Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Jul 31, 2018 11:25am
201 Views
Post# 28391481

RE:Delay

RE:DelayThe NR doesn't really equate to a delay in the trial...
I mean you can easily argue there is 1 month delay starting in Aug and not July...
But it's really the fact that they changed the trial to first be 8-10 weeks to help establish dosage then going into the full trial. 
I'd argue that isn't a delay but rather a change in methodology to get a more effective trial.
That being said, the end result is in fact a much later target for final results (so I guess you can argued delayed results).

Will people bail, yes I'm sure some will. Will people stick around, I'm sure the majority will.
I agree little major catalyst till then. Maybe a surprise if Citgenix can get their act together and be profitable (not holding my breath). Maybe a regional deal which could get us back over 0.40. 
But I do see a window where sometime between Aug/Dec we may dip as log as 0.25. I don't think we will see it close that low, I'm just saying one big dump and we get there.

All and all, I'm still a sit and hold. retirement is only 12-24 months away lol.

Bullboard Posts